Novartis: Europe recommends approving Zolgensma

(CercleFinance.com) - A panel of the European medicines regulator has recommended approving Novartis' Zolgensma, currently the only gene therapy for spinal muscular atrophy (SMA).


The Swiss drugmaker's AveXis unit today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the product's conditional marketing authorisation.

SMA is a rare, genetic neuromuscular disease, affecting muscle functions, including breathing, swallowing and basic movements.

The CHMP has also adopted a positive opinion for Cosentyx for the treatment of adult patients with active non-radiographic axial spondyloarthritis, Novartis said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.